Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope.

Dr. Li earned his undergraduate degree from The Ohio State University in Columbus, Ohio, graduating summa cum laude. He then went on to receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He then completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.

Board certified in internal medicine and medical oncology, Dr. Li serves on several national committees focused on his specialty tumor types. He has authored several publications in the peer reviewed literature, and has presented his work nationally.

Location

Duarte - Main Campus

1500 East Duarte Road
Duarte, CA 91010

(626) 256-4673

Education & Experience

Degrees

2009, M.D., Weill Cornell Medical College, New York, NY
2005, B.S., molecular genetics, summa cum laude, The Ohio State University, Columbus, OH

Fellowship

2012-2015, Fellow in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Residency

2009-2012, Internship and Residency in Internal Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY

Professional Experience

2015-present, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

Awards & Memberships

Memberships

American Society of Clinical Oncology
Cancer and Aging Research Group
Phi Beta Kappa
International Society of Geriatric Oncology
Alliance Cancer in the Elderly Committee
SWOG Gastrointestinal Cancer Committee
NANETS Research Committee

Publications

Li D, Crook C, Ballena R, Fakih M. Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution? JCO Oncol Pract. 2021 Feb 17:OP2001018. doi: 10.1200/OP.20.01018. Epub ahead of print. PMID: 33596100.

Kessler J, Singh G, Ituarte PHG, Allen R, Chang S, Li D. A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. J Vasc Interv Radiol. 2021 Mar;32(3):393-402. doi: 10.1016/j.jvir.2020.10.019. Epub 2021 Jan 7. PMID: 33358144.

Li D, Rock A, Kessler J, Ballena R, Hyder S, Mo C, Chang S, Singh G. Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician's Guide to a Complex Illness. JCO Oncol Pract. 2020 Nov;16(11):720-728. doi: 10.1200/JCOOP.20.00010. Epub 2020 Oct 21. PMID: 33085933.

Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol. 2021 Jan;123(1):164-171. doi: 10.1002/jso.26230. Epub 2020 Sep 24. PMID: 32974932.

Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci. 2020 Jul 23;21(15):5232. doi: 10.3390/ijms21155232. PMID: 32718047; PMCID: PMC7432744.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160.

Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930. PMID: 32352498; PMCID: PMC7193528.

Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019 Jun 18;11(6):841. doi: 10.3390/cancers11060841. PMID: 31216701; PMCID: PMC6627588.

Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018 Jun;19(6):e305-e316. doi: 10.1016/S1470-2045(18)30348-6. Epub 2018 Jun 1. PMID: 29893262.

Li D, Soto-Perez-de-Celis E, Hurria A. Geriatric Assessment and Tools for Predicting Treatment Toxicity in Older Adults With Cancer. Cancer J. 2017 Jul/Aug;23(4):206-210. doi: 10.1097/PPO.0000000000000269. PMID: 28731942.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.

Ratings

4.7

Provider listen carefully to you

4.7

Show respect for what you say

4.6

Rate provider 0-10

4.6

Provider explain in way you understand

4.6

Know important info medical history

4.5

Recommend this provider office

4.5

Spend enough time with you

Reviews

12/22/22

Dr Li is the best! - Verified patient

10/11/22

I liked Dr. LI very much. He answered my questions and explained my treatment process very well. - Verified patient

08/28/22

Dr. Li is wonderful - Verified patient

08/28/22

I love my team! - Verified patient

08/26/22

Good - Verified patient